Эпидемиология и диагностика острой сердечной недостаточности как осложнения острого коронарного синдрома

Автор: Тимофеев А.Б., Замятин М.Н., Денисов Н.Л.

Журнал: Вестник Национального медико-хирургического центра им. Н.И. Пирогова @vestnik-pirogov-center

Рубрика: Обзоры литературы

Статья в выпуске: 4 т.7, 2012 года.

Бесплатный доступ

Короткий адрес: https://sciup.org/140188119

IDR: 140188119

Список литературы Эпидемиология и диагностика острой сердечной недостаточности как осложнения острого коронарного синдрома

  • Батурина О.В., Гиляревский С.Р., Кузьмина И.М. Использование биомаркеров повреждения миокарда для ранней диагностики инфаркта миокарда//1-й съезд врачей неотложной медицины: Материалы съезда. Т. 225. М.: НИИ скорой помощи им. Н.В. Склифосовского, 2012. -С.12.
  • Беленькова Ю.А., Кашталап В.В., Барбараш О.Л. Влияние клинических факторов и маркеров воспаления на прогноз у больных с инфарктом миокарда с подъемом сегмента ST, подвергшихся чрезкожному коронарному вмешательству//Профилактическая медицина -2012 -Т.15, № 2 (выпуск 2) -С. 16-17.
  • Копица Н.П., Белая Н.В., Петенева Л.Л. Прогностическая ценность мозгового натрийуретического пептида у больных острым коронарным синдромом//Международный медицинский журнал -2011. -№ 1. -С. 54-57.
  • Моисеев B.C., Терещенко С.Н., Павликова Е.П., Явелов И.С. Диагностика и лечение острой сердечной недостаточности//Национальные Российские рекомендации/Под ред. Р.Г. Оганов, М.Н. Мамедов. -М.: МЕДИ Экспо, 2009. -С. 321-343.
  • Оганов Р.Г., Шальнова С.А., Калинина А.М. Эпидемиология сердечно-сосудистых заболеваний в России//Профилактика сердечно сосудистых заболеваний: руководство. -М.: ГЭОТАР Медиа, 2009. -Гл. 1. -С. 6-16.
  • Рябов В.В., Суслова Т.Е., Марков В.А. Определение белка, связывающего жирные кислоты, в диагностике острого инфаркта миокарда//Бюллетень СО РАМН. -2005. -№ 3. -С. 26-29.
  • Сердечно-сосудистые заболевания//Информационный бюллетень ВОЗ. -2011. -№ 317: С. 1-4.
  • Шальнова С.А. Эпидемиология сердечно-сосудистых заболеваний и факторы риска в России//Кардиология. Национальное руководство/Под. ред. Ю.И. Беленков, Р.Г. Оганов М.: ГЭОТАР-Медиа, 2008. -Гл.2. -С. 37-51.
  • Явелов И.С. Принципы лечения острой сердечной недостаточности//Медицина неотложных состояний. -2011. -№ 1/2. -С. 171-179.
  • A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators.//N. Engl. J. Med. -1997. -Vol. 337, № 16. -P. 1118-23.
  • Albert NM, Lewis C. Recognizing and managing asymptomatic left ventricular dysfunction: after myocardial infarction//Crit. Care Nurse. -2008. -Vol. 28, № 2. -P. 20-37.
  • Aliberti S., Piffer F., Brambilla A.M., at al. Acidemia does not affect outcomes of patients with acute cardiogenic pulmonary edema treated with continuous positive airway pressure//Crit. Care. -2010. -Vol. 14, № 6. R.196.
  • Antman E.M., Anbe D.T., Armstrong P.W. et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction -executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction)//Circulation. -2004. -Vol. 110, Iss. 5. -P. 588-636.
  • Aouifi A., Piriou V., Bastien O., et al. Usefulness of procalcitonin for diagnosis of infection in cardiac surgical patients.//Crit. Care Med. -2000 -Vol. 28, Iss.9, -P. 3171-3176.
  • Boscheri A., Wunderlich C., Langer M., at al. Correlation of heart-type fatty acid-binding protein with mortality and echocardiographic data in patients with pulmonary embolism at intermediate risk//Am. Heart J. -2010 -Vol. 160, Iss.2, -P. 294-300.
  • Bristow M. Management of Heart Failure.//Heart Disease. A Textbook of Cardiovascular Medicine/Ed. by E. Braunwald, D. Zipes, P. Libby. -6th Edition. -W.B. Saunders Co, 2001 -P. 635-651.
  • Bruins Slot M.H., Reitsma J.B., Rutten F.H., Hoes A.W., van der Heijden G.J. Heart-type fatty acid-binding protein in the early diagnosis of acute myocardial infarction: a systematic review and meta-analysis//Heart -2010. -Vol. 96, Iss. 24. -P.1957-1963.
  • Buerke M., Lemm H., Dietz S., et al. Pathophysiology, diagnosis, and treatment of infarction-related cardiogenic shock.//Herz. -2011.-Vol. 36, Iss. 2. -P. 73-83.).
  • Cotter G., Williams S.G., Vered Z., et al. Role of cardiac power in heart failure//Curr. Opin. Cardiol. -2003. -Vol. 18, Iss.3. -P. 215-222.
  • Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)//Eur. J. Heart Fail. -2008. -Vol.10, Iss.10. -P. 933-989.
  • Dutka D.P., Elborn J.S., Delamere F., et al. Tumour necrosis factor alpha in severe congestive cardiac failure.//British heart journal. -1993.-Vol. 70, Iss. 2. -P. 141-143.
  • Flachskampf F.A., Schmid M., Rost C., et al. Cardiac imaging after myocardial infarction//Eur. Heart J. -2011. -Vol. 32, Iss.3. -P. 272-283.
  • Fonarow G.C. Epidemiology and risk stratification in acute heart failure//Am. Heart J. -2008 -Vol. 155, Iss.2. -P. 200-272.
  • Gheorghiade M., Fonarow G.C. Management of post-myocardial infarction patients with left ventricular systolic dysfunction//Am. J. Med. -2007. -Vol. 120, Iss. 2. -P. 109-120.
  • Glatz J.F., van Bilsen M., Paulussen R.J. et al. Release of fatty acid-binding protein from isolated rat heart subjected to ischemia and reperfusion or to the calcium paradox//Biochim. Biophys Acta. -1988. -Vol. 961, № 1. -P. 148-152.
  • Hasdai D., Topol E.J., Kilaru R., et al. Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating STsegment elevation acute myocardial infarction: Lessons from 4 international fibrinolytic therapy trials//Am. Heart J. -2003. -Vol. 145, Iss.1. -P. 73-79.
  • Havashida N., Chihara S., Akasu K. et al. Plasma and urinary levels of heart fatty acid binding protein in patients undergoing cardiac surgery.//Jpn. Circ. J. -2000. -Vol. 64, №1. -P. 18-22.
  • Hochman J.S. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm//Circulation. -2003. -Vol. 107, Iss. 24. -P. 2998-3002.
  • Ilva T., Lassus J., Siirila-Waris K., at al. Clinical significance of cardiac troponins I and T in acute heart failure//Eur. J. Heart Fail. -2008 -Vol.10, Iss.8. -P. 772-779.
  • Jeger R.V., Radovanovic D., Hunziker P.R. et al. Ten-Year Trends in the Incidence and Treatment of Cardiogenic Shock//Ann. Intern. Med. -2008. -Vol. 149, №9, P. 618-26.
  • Khan S.Q., Dhillon O.S., O’Brien R.J. et al. C-Terminal Provasopressin (Copeptin) as a Novel and Prognostic Marker in Acute Myocardial Infarction. Leicester Acute Myocardial Infarction Peptide (LAMP) Study//Circulation -2007 -Vol. 115, Iss16. -P. 2103-2110.
  • Lukaszewicz A.C., Payen D. Similarities of the clinical aspects of sepsis and noninfectious SIRS//Sepsis and non-infectious systemic Inflammation: from biology to critical care/Ed. by J.-M. Availlon, C. Adrie -Wiley-Blackwell, 2009. -P. 41-56.
  • McCann C.J., Glover B.M., Menown I.B. et al. Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T//Eur. Heart J. -2008. -Vol. 29, Iss.23. -P. 2827-2828.
  • McMurray J.J., Adamopoulos S., Anker S.D. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC//Eur. Heart J. -2012. -Vol. 33, Iss.14. -P. 1787-1847.
  • Menon V., Hochman J. Management of cardiogenic shock complicating acute myocardial infarction//Heart. -2002. -Vol. 88, Iss.5. -P. 531-537.
  • Muehlschlegel J.D., Perry T.E., Liu K.Y., at al. Heart-type fatty acid binding protein is an independent predictor of death and ventricular dysfunction after coronary artery bypass graft surgery//Anesth. Analg. -2010 -Vol. 111, № 5. -P. 1101-1109.
  • Munoz FJ, Thomas B. Cardiogenic Shock.//Chest. -2004. -Vol. 126, Iss. 1. -P. 312-313.
  • Oduncu V., Erkol A., Tanalp A.C., at al. In-hospital prognostic value of admission plasma B-type natriuretic peptide levels in patients undergoing primary angioplasty for acute ST-elevation myocardial infarction//Turk. Kardiyol. Dern. Ars. -2011 -Vol. 39, Iss.7. -P. 540-548.
  • Parenica J., Kala P., Jarkovsky J., at al. Acute heart failure and early development of left ventricular dysfunction in patients with ST segment elevation acute myocardialinfarction managed with primary percutaneous coronary intervention//Vnitr. Lek. -2011. -Vol. 57, Iss.1.-P. 43-51.
  • Peacock W.F., Nowak R., Christenson R., at al. Short-term mortality risk in emergency department acute heart failure//Acad. Emerg. Med. -2011 -Vol. 18, Iss.9. -P.947-958
  • Prondzinsky R., Werdan K., Buerke M. Cardiogenic shock: pathophysiology, clinics, therapeutical options and perspectives//Der Internist. -2004 -Vol. 45, № 3. -P. 284-295.
  • Ryan T.J., Antman E.M.,Brooks N.H. еt al., 1999 Update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)//Circulation. -1999. -Vol. 100, Iss.9. -P. 1016-1030.
  • Sakhuja R., Green S., Oestreicher E.M., Amino-terminal pro-brain natriuretic peptide, brain natriuretic peptide, and troponin T for prediction of mortality in acute heart failure//Clin. Chem. -2007. -Vol. 53, №3, -P.412-20.
  • Santoro G.M. Carrabba N, Migliorini A. Acute heart failure in patients with acute myocardial infarction treated with primary percutaneous coronary intervention//Eur. J. Heart Fail. -2008. -Vol. 10, Iss.8. -P. 780-785.
  • Shochat M., Shotan A., Trachtengerts V., et al. A novel radiological score to assess lung fluid content during evolving acute heart failure in the course of acute myocardial infarction.//Acute Card. Care -2011. -Vol. 13, Iss.2. -P. 81-86.
  • Spencer F.A., Meyer T.E., Goldberg R.J., et al. Twenty year trends (1975-1995) in the incidence, in-hospital and long-term death rates associated with heart failure complicating acute myocardial infarction: a community-wide perspective//J. Am. Coll. Cardiol. -1999. -Vol. 34, Iss.5. -P. 1378-1387.
  • Spencer F.A., Meyer T.E., Gore J.M., et al. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure: the National Registry of Myocardial Infarction//Circulation. -2002. -Vol. 105, Iss. 22. -P. 2605-2610.
  • Steg P.G., Dabbous O.H., Feldman L.J., et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE)//Circulation. -2004. -Vol. 109, Iss. 4 -P. 494-499.
  • Tan L.B. Cardiac pumping capability and prognosis in heart failure//The Lancet -1986. -Vol. 328, №8520. -P. 1360-1363.
  • Tang W.H., Francis G.S., Morrow D.A. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure//Circulation. -2007 -Vol. 116, Iss.5. -P. e99-e109.
  • Van de Werf F., Ardissino D., Betriu A. et al. Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology//Eur. Heart J. -2003. -Vol. 24, Iss.1. -P. 28-66.
  • Van Nieuwenhoven F.A., Kleine A.H., Wodzig WH. et al. Discrimination between myocardial and skeletal muscle injury by assessment of the plasma ratio of myoglobin over fatty acid binding protein//Circulation. -1995. -Vol.92, Iss.10. -P. 2848-2854.
  • Viswanathan K., Kilcullen N., Morrell C., at al. Heart-type fatty acid-binding protein predicts long-term mortality and re-infarction in consecutive patients with suspected acute coronary syndrome who are troponin-negative//J. Am. Coll. Cardiol. -2010 -Vol. 55, Iss.23 -P. 2590-2598.
  • Werdan K., Rufi M., Buerke M., et al. Cardiogenic Shock Due to Myocardial Infarction: Diagnosis, Monitoring and Treatment: A German-Austrian S3 Guideline//Dtsch. Arztebl. Int. -2012. -Vol. 109, Iss.19. -P. 343-351.
  • White H.D., Barbash G.I., Califf R.M., et al. Age and Outcome With Contemporary Thrombolytic Therapy Results From the GUSTO-I Trial//Circulation. -1996. -Vol. 94, Iss. 8. -P. 1826-1833.
  • Will K., Wodzig H., Pelsers M.M., van der Vusse G.J., et al. One-step enzyme-linked immunosorbent assay (ELISA) for plasma fatty acid-binding protein//Ann. Clin. Biochem. -1997. -Vol.34, № 3. -P. 263-268.
  • Williams S.G., Cooke G.A., Wright D.J. еt al. Peak exercise cardiac power output; a direct indicator of cardiac function strongly predictive of prognosis in chronic heart failure//Eur. Heart J. -2001. -Vol. 22, Iss.16. -P. 1496-1503.
Еще
Статья обзорная